Clinical Trials Sponsored by Humanitas Global Development

Total 293 results

Medicines Development for Global Health

Completed

Dose-finding Study of Moxidectin for Treatment of Scabies

Scabies

Australia, Austria, France
Medicines Development for Global Health

Active, not recruiting

Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis

Onchocerciasis

Congo, The Democratic Republic of the
Medicines Development for Global Health

Completed

A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years

Onchocerciasis

Ghana
Medicines Development for Global Health

Recruiting

Efficacy and Safety Study of Moxidectin in Adults With Scabies

Scabies

United States, Honduras
Medicines Development for Global Health

Recruiting

Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

Onchocerciasis

Côte D'Ivoire, Congo, The Democratic Republic of the
Medicines Development for Global Health

Completed

Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers

QT Effects in Healthy Volunteers

United States
Global Alliance for TB Drug Development

Recruiting

Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis

Drug Sensitive Tuberculosis | Pulmonary Tuberculosis | Pulmonary TB

Philippines, South Africa, Tanzania, Georgia, Uganda
Global Alliance for TB Drug Development

Active, not recruiting

A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers (PaSEM)

Tuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant | Tuberculosis, MDR | Drug-Resistant Tuberculosis

Georgia, South Africa
Global Alliance for TB Drug Development

Completed

Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis (ZeNix)

Tuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant | Extensively Drug-Resistant Tuberculosis | Tuberculosis, MDR | XDR-TB | Pre-XDR-TB

South Africa, Russian Federation, Georgia, Moldova, Republic of
Global Alliance for TB Drug Development

Completed

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis Infection

United States
Global Alliance for TB Drug Development

Completed

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis Infection

United States
SPD Development Company Limited
WCCT Global

Completed

Clearblue Pregnancy Test Lay User Usage Study

Pregnancy

United States
Global Alliance for TB Drug Development

Completed

A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis

Pulmonary Tuberculosis

South Africa
Global Alliance for TB Drug Development

Completed

Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam

Tuberculosis

United States
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

Tuberculosis

United States
Global Alliance for TB Drug Development

Completed

A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)

Pulmonary Tuberculosis

South Africa
Global Alliance for TB Drug Development

Completed

PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis

Pulmonary Tuberculosis

South Africa
Cytokinetics
Astellas Pharma Global Development, Inc.

Completed

A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

Spinal Muscular Atrophy

United States, Canada
Global Alliance for TB Drug Development

Completed

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)

Pulmonary Tuberculosis
Global Alliance for TB Drug Development

Terminated

A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

Tuberculosis
Global Alliance for TB Drug Development

Completed

PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)

Tuberculosis

United States
Global Alliance for TB Drug Development

Completed

A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. (NC-005)

Tuberculosis

Tanzania, South Africa, Uganda
Global Alliance for TB Drug Development

Completed

Shortening Treatment by Advancing Novel Drugs (STAND)

Tuberculosis, Pulmonary, Drug Sensitive | Tuberculosis, Pulmonary, Multi Drug-resistant

South Africa, Zambia, Georgia, Philippines, Kenya, Malaysia, Tanzania, Uganda
Global Alliance for TB Drug Development

Completed

A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects. (CL-004)

Tuberculosis

United States
Global Alliance for TB Drug Development

Completed

Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)

Pulmonary Tuberculosis

Tanzania, South Africa
Global Alliance for TB Drug Development

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid

Tuberculosis | Tuberculosis, Pulmonary

United States
Global Alliance for TB Drug Development

Completed

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)

Pulmonary Tuberculosis

South Africa
Global Alliance for TB Drug Development

Completed

Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-003)

Tuberculosis

United States
Global Alliance for TB Drug Development

Completed

Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

Tuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant | Tuberculosis, MDR | Drug-Resistant Tuberculosis

Tanzania, Georgia, Russian Federation, Brazil, Malaysia, Philippines, South Africa, Uganda
Global Antibiotics Research and Development Partnership

Active, not recruiting

Zoliflodacin in Uncomplicated Gonorrhoea

Gonorrhea

United States, Belgium, South Africa, Netherlands, Thailand
Global Alliance for TB Drug Development

Completed

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Tuberculosis | Tuberculosis, Pulmonary

United States
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
Global Alliance for TB Drug Development

Completed

A Study in Two Panels of Healthy Adult Participants to Assess Single-Dose Immediate-Release and Single-Dose Dispersible Formulations of Pretomanid

Multi-drug Resistant Tuberculosis

United States
SPD Development Company Limited
WCCT Global

Completed

Clearblue Pregnancy Test - Lay User Study

Pregnancy

United States
Global Alliance for TB Drug Development

Completed

Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009) (CL-009)

Tuberculosis

United States
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

Tuberculosis | Tuberculosis, Pulmonary

United States
Global Alliance for TB Drug Development

Completed

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)

Pulmonary Tuberculosis

South Africa
Global Alliance for TB Drug Development

Completed

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) (NC-003)

Pulmonary Tuberculosis

South Africa
Northwestern University
Astellas Pharma Global Development, Inc.

Completed

Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI

Myocardial Ischemia

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats (OPTION-VMS)

Hot Flashes

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease

Intraoperative Ureter Visualization | Abdominolpelvic Surgery

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Chronic Kidney Disease | Renal Anemia

Romania, Spain, Belgium, Germany, Norway, Slovakia, Denmark
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery

Intraoperative Ureter Visualization | Abdominolpelvic Surgery

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study of ASP2138 in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer

Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Japan, Korea, Republic of
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma (ILUSTRO)

Gastric Cancer | Pharmacokinetics of Zolbetuximab | Gastro-esophageal Junction (GEJ) Cancer | Pharmacokinetics of Oxaliplatin | Pharmacokinetics of Fluorouracil Bolus (5-FU)

United States, Italy, Japan, Korea, Republic of, Taiwan, France
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer | Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States, Korea, Republic of, Japan, China, France, Turkey, Italy, Australia, Brazil, Ireland, Mexico, Spain, Taiwan
Astellas Pharma Global Development, Inc.

Completed

A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well

Renal Impairment | Healthy Volunteers

United States, Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function

Renal Impairment | Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States

Clinical Trials Sponsored by Humanitas Global Development

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations